The contribution of the candidate gene CTLA4 to type 1 diabetes is not well established. Although several polymorphisms have been repeatedly associated to the disease, several studies have not confirmed the association. The joint analysis of three SNPs in the CTLA4 promoter region (À1722, À1661, and À319), one SNP in the first exon (+49), and one dinucleotide repeat in the 3 0 untranslated region, in a case-control study in a North African population, shows a strong association of the CTLA4 region with the disease. The À1661G allele showed a significant association with an odds ratio of 2.13. Moreover, the internal structure of the dinucleotide repeat has been deeply analyzed. The present results reveal the importance of polymorphisms in the CTLA4 promoter region, their probable role in gene expression and, ultimately, their relation to the etiology of type 1 diabetes. Previous contradictory association studies might be due to the effect of linkage disequilibrium between the polymorphism analyzed and the alteration within the CTLA4 region. This alteration may be different depending on the genetic background of the population. The present work stresses the need to perform exhaustive analysis of the promoter region polymorphisms in order to detect association with the disease.
Introduction
Type 1 diabetes (T1D) is a genetically complex disease that results from the T-cell-mediated destruction of pancreatic beta cells. Whole genome searches have identified at least 20 chromosomal regions with putative association to T1D, 1, 2 indicating that this is a disorder with a complex genetic base. The major genetic locus (IDDM1) is situated in the HLA class II region on chromosome 6p21, and a second locus (IDDM2) in the insulin region on chromosome 11p15. Besides these genomic regions, only a few candidate regions have been shown to harbor susceptibility genes. 3, 4 The CTLA4 gene, referred to as IDDM12 and located at 2q33, is a good candidate gene for susceptibility to T1D. 3 It encodes the T-cell receptor involved in the control of T-cell proliferation and mediates T-cell apoptosis. [5] [6] [7] CTLA4-deficient mice develop a severe lymphoproliferative disease with multiorgan lymphocytic infiltration and tissue destruction, including the pancreas, 8 revealing an immunosuppressive role for the CTLA4 protein.
Thus, CTLA4 may be involved in the pathogenesis of multiple T-cell-mediated autoimmune diseases.
Evidence for association between the CTLA4 gene and T1D has been reported in a large number of families and in large case-control studies by linkage and/or association analyses. Two polymorphisms in the gene have been widely analyzed in T1D patients from several ethnic and geographical populations: (i) an A-G substitution at position +49, in exon 1, encoding the leader peptide; 9 and, (ii) a dinucleotide repeat at position 642 of the 3 0 untranslated region. 10 These polymorphisms seem to be associated with the genetic susceptibility to T1D in several populations, although conflicting data also exist.
Linkage and association of the CTLA4 locus were first reported in Italian and Spanish families. 3 These results were confirmed in other populations such as Asians, populations of European ancestry, and Mexican-Americans. [11] [12] [13] [14] [15] [16] Nevertheless, in other studies with populations of European ancestry, no evidence of association was found. [17] [18] [19] [20] Recently, an association with a novel polymorphism at position 159 has been found in West African populations, but not in Chinese. And conversely, the CTLA4+49 (A-G) marker conferred a risk of T1D in Chinese but not in west Africans. 21 Therefore, the causal mechanism by which the CTLA4 region may be involved in susceptibility to T1D is not clear and the association results differ between populations. Therefore, the replication of results of association in populations of different ethnic background is needed to have a clear association with a specific allele or haplotype independent of the genetic background of the population.
Recent association studies have stressed the need for a haplotype approach instead of relying on individual single nucleotide polymorphisms (SNPs). Given that close markers in a genomic region tend to be in linkage disequilibrium (LD), some SNPs at a given locus yield redundant information whereas others are essential in association studies. These essential SNPs are referred to as 'haplotype-tagging SNPs (htSNPs)'. 22 Recently, within the CTLA4 region, 16 SNPs have been detected, 22 from which only four were also described in dbSNP (http:// www.ncbi.nlm.nih.gov/SNP/). The htSNPs of the CTLA4 were already described in an European sample of 384 individuals.
The present study analyzes four SNPs defined by Johnson et al 22 in a South Moroccan sample, and determines the structure of the dinucleotide repeat in the 3 0 untranslated region of the CTLA4 gene. To our knowledge, this report is the first to (i) analyze the association of multiple polymorphisms (four SNPs and a dinucleotide repeat) in the CTLA4 region with T1D; and (ii) perform a case/control study for the CTLA4 region in a North African population.
Results
The SNPs analyzed are four of the five htSNPs defined by Johnson et al 22 for the CTLA4 gene. Based on their data of 384 European individuals, the combination of the present four SNPs describes common haplotypes with a frequency over 8%. The four SNPs were analyzed in 118 Moroccan T1D patients from the Souss area and 114 healthy controls from the same geographical area. Allele and genotype frequencies of the CTLA4 SNPs are shown in Table 1 . No departure from Hardy-Weinberg equilibrium (P40.05) was observed either in controls or in T1D patients. In order to detect any associations between T1D patients and the SNPs genotyped, allele and genotype distributions from patients and controls were compared. Allele and genotype distributions of SNPs À1722 and +49 do not differ significantly between T1D patients and healthy control subjects. The frequency of the À319T allele is nominally significantly increased in T1D patients compared to controls (P ¼ 0.045), although it ceases to be significant when the Bonferroni correction is applied. In this case, the odds ratio (OR) did not reach statistical significance maybe due to the low frequency of the -319T allele (5% in T1D patients and 2% in controls). On the other hand, the frequency of the À1661G allele is significantly higher in T1D patients relative to controls with an odds ratio of 2.13 (95% CI: 1.39-3.24, P ¼ 0.0004). Moreover, when we focus on the frequency of the -1661 genotypes, the A/A genotype frequency was significantly lower in T1D patients compared to controls (44% vs 67%), whereas the A/G genotypes were significantly higher in T1D patients (43% vs 27% in controls).
SNPs haplotypes
Besides the SNP analysis and in order to detect any possible haplotype susceptibility to T1D, the CTLA4 Comparing cases and controls, the TGCA haplotype appears to be more frequent in the T1D population (OR: 2.02, 95% CI: 1.29-3.17, P ¼ 0.001), whereas the most frequent haplotype TACA in both samples shows a lower frequency in T1D patients (OR: 0.51, 95% CI: 0.35-0.74, P ¼ 0.0004). When haplotypes bearing allele -1661G were grouped, the differences were also significant with a similar odds ratio (OR: 2.17, 95% CI: 1.42-3.30).
Since the genome is composed of blocks of strong LD, haplotype reconstruction in association analyses is needed. All the SNPs analyzed in the present work are located within a region of less than 2 kb. In order to test for LD between the SNPs typed, the D 0 values between the four SNPs were calculated using the estimated haplotype frequencies. Table 3 CTLA4 (AT) n microsatellite structure Several homozygous individuals for different alleles were sequenced in order to determine the structure of the CTLA4 dinucleotide repeat (AT) n and the exact number of AT repeats. A total of 22 alleles, ranging from 74 to 122 bp, were detected during the analysis of 130 T1D patients and 129 healthy controls. The repeat motif observed was (AT) 3 AC (AT) n , where n ranges from 7 to 30 in the present samples. For instance, homozygotes for a 74 bp fragment carry an (AT) 3 AC (AT) 7 sequence, which has been designated as allele 7. This is the smallest allele found in our sample set and corresponds to allele 11 (11 estimated AT repeats) found in a Russian sample previously described. 23 The allele distribution shows a multimodal pattern with a mode at 7 repeats (Table 4) . Table 4 Absolute allele frequencies of the dinucleotide repeat located to 3 0 of the CTLA4 gene (dinucleotide structure is (AT) 3 AC(AT) n , where n is the number of AT repeats, which is shown in the first column). Alleles 7 and 16 are the most frequent both in T1D patients (40% and 13%) and controls (54% and 11%). The frequency of allele 7 is found to be significantly decreased (w 2 ¼ 10.24, 1 d.f., P ¼ 0.0013) in T1D patients compared to controls (OR: 0.56, 95% CI: 0.39-0.80, P ¼ 0.001). The distribution of the 64 (AT) n genotypes observed (data not shown) does not differ significantly between patients and controls, given that most genotypes are rare. There were only two genotypes at frequencies over 5%: genotype 7/7 (16.5% in T1D patients vs 28% in controls) and genotype 7/16 (9% and 14%, respectively).
Repeat units (AT)3AC(AT)n Patients (2N=254) Controls (2N=256)
CTLA4 SNPs-(AT) n haplotypes Haplotype frequencies were estimated on the basis of complete genotypes for the four SNPs and the (AT) n microsatellite typed. This analysis revealed 53 haplotypes in T1D patients and 46 haplotypes in controls (data not shown). The most frequent haplotypes in both groups were TACA7 (34% in T1D patients vs 45% in controls) and TACG16 (9% vs 6 %). After Bonferroni correction, no SNPs-(AT) n haplotypes showed a significant association with the disease.
Discussion
Although the functional implication of CTLA4 polymorphisms in autoimmune diseases is not well established, the (AT) n polymorphism located at the 3 0 end untranslated region has been related to mRNA stability, especially that of cytokine genes, 24 and polymorphisms within the promoter and first exon of the CTLA4 gene have been suggested to be related to the expression levels of CTLA4 molecules. 25 The present analysis confirms the implication of the CTLA4 gene region (locus IDDM12) with T1D. Out of the five polymorphisms genotyped in the region (three SNPs in the promoter region, one in the first exon, and the AT repeat in the 3 0 end of the gene), two SNPs (À1661 and À319) and one allele of the microsatellite (allele 7) have shown differences between T1D patients and controls. A strong association of the À1661G allele, with an odds ratio of 2.13, has been found in the present case-control study.
The polymorphism at position +49 in the first exon of the gene and the AT repeat have been widely analyzed in T1D patients from several ethnic populations. These two polymorphisms have been suggested to confer susceptibility to T1D in several populations of European ancestry, but the results are not confirmed in other studies. Significant association of the +49A allele has been found and confirmed in multiple studies, whereas in the present work, similar frequencies of the +49A allele are found in cases and controls. The CTLA4+49 marker is not associated to T1D in the present sample set and does not seem to confer any genetic susceptibility to T1D in North Africans. This result is consistent with the absence of association of this marker with T1D in West Africans 21 and Asians. 11, 13, 19 The absence of association between different alleles of the dinucleotide (AT) repeat and the level of CTLA4 expression as well as the stability of CTLA4 mRNA has been reported. 25 Therefore, the differences of frequencies found for the smallest allele (allele 7) of the (AT) n repeat in our population and the previously observed association between T1D and longer alleles may be the result of LD between specific microsatellite alleles and the true etiological factor of susceptibility. In the present analysis, the differences found for allele 7 can be explained as a result of LD with the promoter htSNPÀ1661 (Po0.05 in controls, test of genotype association).
Besides À1661, +49, and the AT repeat, two other polymorphisms (À1771, À319) have been analyzed in the CTLA4 region. The CTLA4À319 (previously named À318) has been related to autoimmune diseases but not to T1D. The À319T allele is present at low frequency in North Africans (2%) vs the 8-10% found in European populations, 26, 27 whereas the Chinese population presents higher frequencies (18%) of the T allele. 27 In the present analysis, although a slightly significant increase of the À319T allele is found in T1D patients, the odds ratio does not reach statistical significance. Therefore, we can conclude that this allele does not seem to be associated with the genetic susceptibility to T1D in the present sample set. Finally, the CTLA4À1722 has not shown differences between cases and controls.
The SNP-haplotype analysis performed shows a significant increase of the TGCA and decrease of TACA haplotypes in T1D patients compared to controls. These statistical differences reflect a significant increased frequency of the À1661G allele in T1D patients since the odds ratio shown by the -1661G allele is even higher than that presented by the TGCA haplotype. Consideration of haplotypes rather than of single sites may allow to detect an interaction between sites or a role for a particular genetic backgroud; in this case, however, it has revealed that all of the risk for T1D in CTLA4 can be attributed to a single SNP allele, namely À1661G.
The analysis of four SNPs in our population reveals a strong association of SNPÀ1661 with T1D. No association is found for the three other SNPs including CTLA4+49 that has been recurrently associated in other populations. 11, 13, 15, 21 If we had just analyzed the CTLA4+49 marker in our sample set, we would have failed to find any association with T1D. Thus, a similar analysis of different SNPs would be required for other ethnic groups that have failed to show any association between the CTLA4 region and T1D. This fact stresses the importance of association confirmation in different populations in order to describe positive associations regardless of the genetic background of the samples.
The association found between SNPÀ1661 and T1D in North Africans would be related to different expression of the CTLA4 gene. The À1661A/G promoter polymorphism may affect the CTLA4 gene expression in a similar way as reported for the SNPÀ319 promoter polymorphism. 25 Therefore, future expression analyses should consider position À1661 in order to detect differences in CTLA4 expression.
Material and methods

Genotyping of SNPs and AT repeat
The present analysis follows all the guidelines for DNA polymorphism-disease association studies proposed by Cooper et al. 28 A total of 259 individuals from the Souss region of Morocco were analyzed: 130 diabetic patients and 129 controls. All subjects were Moroccans; 80% described themselves as Berbers while the remaining CTLA4 association with type 1 diabetes in South Moroccans L Bouqbis et al 20% were Arabs. However, both populations are not genetically differentiated. [29] [30] [31] [32] All individuals had previously been typed for HLA-DRB1, ÀDQA1 and ÀDQB1. 33 Genomic DNA was extracted following standard methods.
Four single nucleotide positions at the CTLA4 region were analyzed by using the SNaPshot TM Multiplex Kit (Applied Biosystems), which consists of a single-base primer extension which uses fluorescently labeled ddNTPs to interrogate SNPs. The four SNPs are located at positions À1722, À1661, À319, and +49 with respect to the initiator Met codon of the CTLA4 gene. The region containing the four SNPs was amplified using primers FCTLA4 (5 0 -TGCTCCTCTACATAATACTTC-3 0 ) and RCTLA4 (5 0 -CTGCTGAAACAAATGAAACCC-3 0 ), with the following cycling conditions: 941C for 5 min; 35 cycles of 941C for 30 s, 581C for 30 s, and 721C for 30 s; and a final elongation step of 721C for 5 min. The 1968-bp amplification products were purified using the QIAquick TM PCR Purification Kit (QIAGEN). The single-base primer extension was performed following supplier's recommendations using four oligonucleotides of different lengths. The sequences of the oligonucleotides were:
, and CTLA4+49 (5 0 -GCTCAGCTGAACCTGGCT-3 0 ). The single-base primer extension was performed in the same reaction for the four oligonucleotides. Unincorporated-labeled ddNTPs were removed by adding one unit of CIP to the primer extension products for 1 h at 371C, followed by 15 min incubation at 721C to inactivate the enzyme. Products were run in an ABI PRISM3100 (Applied Biosystems), and GeneScan TM analysis software (version 3.7) was used to measure fragment sizes using the LIZ-120 (Applied Biosystems) size marker.
The (AT) n dinucleotide repeat located at the 3 0 -end of the CTLA4 locus was PCR-amplified using the primers CTLA4AT1 (5 0 -GCCAGTGATGCTAAAGGTTG-3 0 , labeled with FAM at the 5 0 -end) and CTLA4AT3 (5 0 -CGTGGCTCTATGCACAATAC-3 0 ) with the following cycling conditions: 941C for 5 min; 35 cycles of 941C for 30 s, 581C for 30 s, and 721C for 30 s; and a final elongation step of 721C for 5 min. Products were run in an ABI PRISM3100, and GeneScan TM analysis software (version 3.7) was used to measure fragment sizes using the ROX-500 (Applied Biosystems) size marker. Some homozygous individuals were sequenced using the primer CTLA4AT3 and the Big Dye Terminator (version 3.0) Cycle Sequencing Kit, with AmpliTaq s DNA Polymerase (Applied Biosystems); the products were subsequently run in an ABI PRISM 3100 (Applied Biosystems) automatic sequencer and analyzed using Sequencing Analysis Tm software (version 3.7).
Statistical analysis
Genotype and allele frequencies were estimated by direct counting, and were compared between patients and controls by means of chi-square tests and odds ratios. The Bonferroni correction for multiple testing was applied as required. Haplotype frequencies were estimated with an EM algorithm, as implemented in the Arlequin 2.000 program. 34 LD was assessed by taking the estimated absolute haplotype frequencies rounded to the nearest integer and computing from those D 
